|1.||WO||WO/2014/170866 - PROCESS OF OBTAINING GLYCOPROTEIN COMPOSITION WITH INCREASED GALACTOSYLATION CONTENT||23.10.2014||
||PCT/IB2014/060812||DR. REDDY'S LABORATORIES LIMITED||THUDUPPATHY, Guruvasuthevan Ramasamy|
The invention describes a cell culture process for production of glycoprotein composition with increased galactosylation content while maintaining specific productivity. The process involves culturing cells at high pCO2 and subjecting cells to temperature downshift to obtain a glycoprotein with specific glycoprotein composition.
|2.||WO||WO/2014/155349 - REFOLDING OF PROTEINS||02.10.2014||
||PCT/IB2014/060251||DR. REDDY'S LABORATORIES||PARAYITAM, Bharata, Ratnam|
The present invention is related to a method for refolding of recombinant GCSF that minimizes the generation of oxidized forms of GCSF by optimizing the refolding of inclusion bodies containing recombinant GCSF.
|3.||WO||WO/2014/145710 - PARENTERAL DICLOFENAC COMPOSITION||18.09.2014||
|PCT/US2014/030519||DR. REDDY'S LABORATORIES, INC.||OKUMU, Franklin|
The present application provides parenteral compositions of diclofenac or its pharmaceutically acceptable salt and methods for making and using such compositions. Some of the compositions of the present application has one or more following properties: (1) ready to be injectable, (2) in the form of an oil-in-water emulsion, (3) stable under appropriate storage conditions, (4) containing therapeutically effective amount of diclofenac or its pharmaceutically acceptable salt, (5) sterilizable by filtration (6) containing components acceptable by regulatory agencies (e.g. the FDA), (7) containing low oil content and thus not exacerbating hyerlipidemia, and (8) is neither hyperallergenic nor vein irritating.
|4.||WO||WO/2014/128564 - PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS||28.08.2014||
|PCT/IB2014/000715||DR. REDDY'S LABORATORIES LTD.||NEKKANTI, Vijay, Kumar|
The present application discloses a pharmaceutical composition comprising a class of cholesteryl ester transfer protein (CETP) inhibitors with improved oral bioavailability. The application further discloses compositions comprising a class of CETP inhibitor and at least one surfactant in the form of a solution, suspension, emulsion or a pre-concentrate.
|5.||WO||WO/2014/118685 - METHOD OF ALTERING THE ACIDIC VARIANT CONTENT OF ANTIBODY||07.08.2014||
|PCT/IB2014/058553||DR. REDDY'S LABORATORIES LIMITED||KULKARNI, Samir, R.|
A method of altering the amount of acidic variants in antibody composition, in particular, employs a cation exchange chromatography with varying amounts of wash buffer column volume to alter the acidic variant content of the antibody.
|6.||WO||WO/2014/083512 - PROCESS FOR PREPARATION OF ABIRATERONE ACETATE||05.06.2014||
|PCT/IB2013/060441||DR. REDDY'S LABORATORIES LIMITED||DAHANUKAR, Vilas Hareshwar|
The present invention relates to process for the preparation of abiraterone acetate, its salts and intermediates thereof, crystalline forms of abiraterone acetate salts and purification of abiraterone acetate.
|7.||WO||WO/2014/076568 - PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS||22.05.2014||
|PCT/IB2013/002909||DR. REDDY'S LABORATORIES LTD.||PADHI, Bijay, Kumar|
The present application discloses a pharmaceutical composition comprising a class of CETP inhibitors with improved oral bioavailability. The application further discloses compositions comprising a class of CETP inhibitor and at least one solubility improving material and optionally one or more wetting agents.
|8.||WO||WO/2014/072961 - POLYMORPHIC FORMS OF SUVOROXANT||15.05.2014||
|PCT/IB2013/060080||DR. REDDY'S LABORATORIES LIMITED||PEDDY, Vishweshwar|
Present invention relates to crystalline form of suvorexant, amorphous form of suvorexant, amorphous solid dispersion of suvorexant, processes for their preparation and pharmaceutical dosage form thereof.
|9.||WO||WO/2014/045263 - PROCESS FOR PREPARATION OF INTERMEDIATES OF TELAPREVIR||27.03.2014||
|PCT/IB2013/058808||DR. REDDY'S LABORATORIES LIMITED||IQBAL, Javed|
Provided are novel processes for preparation of (1S, 3aR, 6aS)-octahydrocyclopenta[c]pyrrole-1-carboxylic acid and its derivatives; land their use in preparation of Telaprevir.
|10.||WO||WO/2014/041487 - ENZALUTAMIDE POLYMORPHIC FORMS AND ITS PREPARATION||20.03.2014||
|PCT/IB2013/058455||DR. REDDY'S LABORATORIES LIMITED||PEDDY, Vishweshwar|
The present application relates to crystalline and amorphous forms of Enzalutamide. The present application further relates to amorphous solid dispersions of Enzalutamide with pharmaceutically acceptable carriers. The present application also relates to a process for the preparation of Form R1 of Enzalutamide.